In the latest close session, Humacyte, Inc. (HUMA) was down 7.69% at $2.28. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, added 0.18%. The company's shares have seen an increase of 2.49% over the last month, surpassing the Medical sector's loss of 1.56% and falling behind the S&P 500's gain of 4.97%.The investment community will be closely monitoring the performance of Humacyte, Inc. in its forthcoming earnings report ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characte ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Amgen (AMGN) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Amgen is one of 986 individual stocks in the Medical sector. Collectively, these companies sit at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. Th ...

Group 1: Stock Performance - Novavax (NVAX) closed at $6.97, with a daily increase of +1.9%, outperforming the S&P 500's gain of 0.14% [1] - Over the last month, Novavax shares decreased by 1.44%, while the Medical sector lost 1.34% and the S&P 500 gained 3.97% [1] Group 2: Upcoming Earnings - The upcoming EPS for Novavax is projected at -$0.12, indicating a 112.12% decline compared to the same quarter last year [2] - Revenue is estimated at $130.5 million, reflecting a 68.59% decrease from the corresponding quarter of the previous year [2] Group 3: Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $2.65 per share, representing a +315.45% change from the previous year [3] - Revenue for the fiscal year is estimated at $1.07 billion, indicating a +56.76% change from the prior year [3] Group 4: Analyst Estimates and Rankings - Recent modifications to analyst estimates for Novavax indicate changing near-term business trends, with positive revisions suggesting optimism [4] - The Zacks Rank system, which includes estimate changes, currently ranks Novavax at 3 (Hold) [6] Group 5: Valuation Metrics - Novavax has a Forward P/E ratio of 2.58, which is a discount compared to the industry average Forward P/E of 18.51 [7] - The PEG ratio for Novavax is 0.06, significantly lower than the industry average PEG ratio of 1.54 [8] Group 6: Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Novavax, has a Zacks Industry Rank of 74, placing it in the top 30% of over 250 industries [8][9] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [9]

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering CorMedix (CRMD) , which belongs to the Zacks Medical - Biomedical and Genetics industry.When looking at the last two reports, this pharmaceutical and medical device company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 24.71%, on average, in the last two quarters.For the last reported quarter, CorMedix came ...

Agenus (AGEN) shares ended the last trading session 19.3% higher at $7.06. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 22.8% gain over the past four weeks.Earlier this month, the company announced encouraging clinical data for its combination therapy of botensilimab and balstilimab (BOT/BAL) in patients with microsatellite-stable metastatic colorectal cancer without active liver metastases. In an expanded cohor ...

Company Performance - Moderna's stock closed at $33.64, down 1.87%, underperforming the S&P 500's daily loss of 0.33% [1] - Over the previous month, Moderna's shares gained 25.34%, outperforming the Medical sector's loss of 0.32% and the S&P 500's gain of 4.07% [1] Upcoming Earnings - The upcoming earnings release is anticipated, with an expected EPS of -$2.97, reflecting a 10.81% increase from the same quarter last year [2] - Revenue is forecasted at $130.15 million, indicating a 46% decline compared to the same quarter last year [2] Full-Year Estimates - Zacks Consensus Estimates predict full-year earnings of -$9.81 per share and revenue of $2.08 billion, representing year-over-year changes of -10.6% and -35.83%, respectively [3] - Recent changes in analyst estimates are crucial for investors, as positive revisions indicate optimism regarding business and profitability [3] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown a strong track record, with 1 stocks delivering an average annual return of +25% since 1988 [5] - Currently, Moderna holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate moving 0.26% lower over the last 30 days [5] Industry Overview - The Medical - Biomedical and Genetics industry ranks in the top 31% of all industries, with a current Zacks Industry Rank of 76 [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Core Insights - Certara, Inc. is positioned to potentially continue its earnings-beat streak in the upcoming report, having surpassed earnings estimates by an average of 11.54% in the last two quarters [1][2]. Earnings Performance - In the last reported quarter, Certara achieved earnings of $0.14 per share, exceeding the Zacks Consensus Estimate of $0.13 per share, resulting in a surprise of 7.69% [2]. - In the previous quarter, the company was expected to post earnings of $0.13 per share but delivered $0.15 per share, leading to a surprise of 15.38% [2]. Earnings Estimates and Predictions - Recent estimates for Certara have been trending upward, with a positive Earnings ESP of +2.44%, indicating increased analyst optimism regarding the company's earnings prospects [5][8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing that stocks with this combination beat estimates nearly 70% of the time [6][8]. Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate [7]. - A negative Earnings ESP can reduce the predictive power of the metric, but it does not necessarily indicate an earnings miss [9]. Importance of Earnings ESP - Many companies beat consensus EPS estimates, but this is not the sole reason for share price gains; thus, checking a company's Earnings ESP before quarterly releases is crucial for investment decisions [10].

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $10.79, reflecting a -2.53% change from the previous day's closing price, underperforming the S&P 500's daily gain of 0.28% [1] - The stock has increased by 13.19% over the past month, outperforming the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37% [1] Earnings Projections - The upcoming EPS for Ginkgo Bioworks is projected at -$1.44, indicating a 55.00% increase compared to the same quarter last year [2] - Quarterly revenue is estimated at $43 million, which is a decrease of 23.5% from the year-ago period [2] - For the entire year, the Zacks Consensus Estimates forecast earnings of -$5.56 per share and revenue of $180 million, reflecting changes of +46.33% and -20.72% respectively compared to the previous year [3] Analyst Forecasts - Recent revisions to analyst forecasts for Ginkgo Bioworks are important as they reflect short-term business trends and can indicate analyst optimism about the company's profitability [4] - The Zacks Rank system, which incorporates estimate changes, provides an actionable rating system for investors [5] - Ginkgo Bioworks currently holds a Zacks Rank of 2 (Buy), with the consensus EPS estimate remaining unchanged over the last 30 days [6] Industry Context - Ginkgo Bioworks is part of the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 77, placing it in the top 32% of over 250 industries [7] - The top 50% rated industries tend to outperform the bottom half by a factor of 2 to 1 [7]

Company Overview - Anavex Life Sciences (AVXL) currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [4] Performance Metrics - Over the past week, AVXL shares have increased by 13.82%, significantly outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 2.88% [6] - In a longer time frame, AVXL's shares have shown a monthly price change of 31.22%, while the industry only experienced a 0.29% increase [6] - For the past quarter, AVXL shares have risen by 21.72%, and over the last year, they have gained 132.9%, compared to the S&P 500's increases of 15.13% and 13.62%, respectively [7] Trading Volume - The average 20-day trading volume for AVXL is 910,751 shares, which serves as a useful indicator of market interest and price movement [8] Earnings Outlook - In the past two months, one earnings estimate for AVXL has been revised upward, while none have been revised downward, leading to an increase in the consensus estimate from -$0.69 to -$0.52 [10] - For the next fiscal year, one estimate has moved upwards with no downward revisions during the same period [10] Conclusion - Considering the strong performance metrics and positive earnings outlook, AVXL is positioned as a promising investment opportunity with a Momentum Score of A [12]